Upload Avatar (500 x 500)
Duan Yi
Basic Medical Sciences
University of Science and Technology of China
Anhui
Language: English, Chinese
Gut Microbiota
Metabolic Diseases
Immune Diseases
Chronic Liver Disease
Biotherapies
Phage Therapy
Microbiome
New Technologies
Molecular Mechanisms
Clinical Value
Areas of Focus
- Impact of gut microbiota on metabolic and immune diseases, especially chronic liver disease
- Development and application of microbiome-related biotherapies, especially phage therapy
- Development of new technologies and methods related to gut microbiota research
Work Experience
- 2022-present - University of Science and Technology of China - Professor, Doctoral Supervisor
- 2017-2022 - University of California, San Diego - Postdoctoral Research Scholar
Academic Background & Achievements
- 2011-2016 PhD in Biochemistry: Texas A&M University
- 2007-2011 Bachelor's in Biological Sciences: University of Science and Technology of China
- Published 35 SCI papers, 17 with IF>10
- Cited over 2700 times, highest single citation 485 times
Publications
- Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease., Duan Y, Llorente C, Lang S, Brandl K, Chu H, Jiang L, et al., 2019
- Novel tripeptide RKH derived from Akkermansia muciniphila protects against lethal sepsis., Xie S, Li J, Lyu F, Xiong Q, et al., Duan Y, Jiang Y, Zhou H, Chen P., 2023
- Phage therapy in gut microbiome., Chen X, Mendes BG, Alves BS, Duan Y., 2023
- Bacteriophages and their potential for treatment of gastrointestinal diseases., Duan Y, Young R, Schnabl B., 2022
- Immune response of an oral Enterococcus faecalis phage cocktail in a mouse model of ethanol-induced liver disease., Mendes BG, Duan Y, Schnabl B., 2022
- CRIg on liver macrophages clears pathobionts and protects against alcoholic liver disease., Duan Y, Chu H, Brandl K, Jiang L, Zeng S, Mendes BG, et al., 2021
- The Candida albicans exotoxin Candidalysin promotes alcohol-associated liver disease., Chu H, Duan Y, Lang S, Jiang L, Wang Y, Llorente C, et al., 2020
- Functional microbiomics reveals alterations of the gut microbiome and host co-metabolism in patients with alcoholic hepatitis., Gao B, Duan Y, Lang S, Barupal D, Wu TC, Valdiviez L, et al., 2020
- The DnaA inhibitor SirA acts in the same pathway as Soj (ParA) to facilitate oriC segregation during Bacillus subtilis sporulation., Duan Y, Huey JD, Herman JK, 2016
- YodL and YisK possess shape-modifying activities that are suppressed by mutations in Bacillus subtilismreB and mbl., Duan Y, Sperber AM, Herman JK, 2016
- Candida albicans-specific Th17 cell-mediated response contributes to alcohol-associated liver disease., Zeng S, Rosati E, Saggau C, Messner B, Chu H, Duan Y, Hartmann P, et al., 2023
- The fecal mycobiome in non-alcoholic fatty liver disease., Demir M, Lang S, Hartmann P, Duan Y, Martin A, Miyamoto Y, Bondareva M, et al., 2022
- Intestinal virome and therapeutic potential of bacteriophages in liver disease., Hsu CL, Duan Y, Fouts DE, Schnabl B., 2021
- Gut microbiome directs hepatocytes to recruit MDSC and promote cholangiocarcinoma., Zhang Q, Ma C, Duan Y, Heinrich B, Rosato U, Diggs L, et al., 2021
- Intestinal virome in patients with alcoholic hepatitis., Jiang L, Lang S, Duan Y, Zhang X, Gao B, Chopyk J, et al., 2020
- Intestinal fungal dysbiosis and systemic immune response to fungi in patients with alcoholic hepatitis., Lang S, Duan Y, Liu J, Torralba MG, Kuelbs C, Ventura-Cots M, et al., 2020
- Intestinal virome signature associated with severity of nonalcoholic fatty liver disease., Lang S, Demir M, Martin A, Jiang L, Zhang X, Duan Y, Gao B, Wisplinghoff H, et al., 2020
- Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice., Hendrikx T, Duan Y, Wang Y, Oh JH, Alexander LM, Huang W, et al., 2019
- Small Metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease., Chu H, Duan Y, Yang L, and Schnabl B, 2019
Awards
- 2019 AASLD Early Career Investigator Award
